HCT response to El Nino drought response
For practitioners in humanitarian and development contexts
This toolkit provides practical guidance to governments, funders, civil society organizations and other implementing partners on conducting a gender analysis and using findings to inform HIV prevention, care and treatment programs with key populations. It outlines considerations and steps for conduc...ting a gender analysis; explores how to engage with stakeholders, including key population members, in a meaningful partnership; shares lessons learned from a comprehensive gender analysis in Kenya and an abridged gender analysis in Cameroon; and provides tools and resources for conducting a gender analysis with key populations.
more
The brochure provides information about a mobile crèche where young children can receive organized care and breastfeeding while the parent participate in the public works.
The 2020 recommendations for the programmatic management of TB preventive treatment are the first to be released under the rubric of WHO consolidated TB guidelines (Module 1 – Prevention). The WHO consolidated TB guidelines will gradually group all TB recommendations and will be complemented by ma...tching modules of a consolidated operational handbook. [1] The handbook will provide practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact. The first handbook module in the series will be on the programmatic management of TB preventive treatment and will accompany the 2020 guidelines.
more
The WHO operational handbook on tuberculosis: tuberculosis preventive treatment is the companion, implementation guide to the 2020 WHO guidelines on TB preventive treatment.[1] Just as these guidelines are the first to be released under the rubric of the WHO consolidated TB guidelines, this handbook... will be the first in a modular series of practical guides meant for the implementers of various aspects of the programmatic management TB.
more
13 May 2021
To avoid a reversal of progress from the adverse impacts of the COVID-19 pandemic, new knowledge and lessons from successful programmatic innovations are urgently needed to improve TB prevention and care. Experience can provide evidence for innovative approaches and strategies to mainta...in and scale up high-quality TB services. WHO therefore called for case studies on programmatic innovations that address emerging challenges in TB prevention and care during the pandemic in order to collect and disseminate the findings to the TB community. Between November 2020 and February 2021, a total of 23 case studies relevant to the call were accepted from 19 countries in the six regions of WHO. The lessons learnt from these country activities to ensure the continuity of essential services like TB care in the face of the crippling crisis may also inform strategies for minimizing the impact of future emerging pathogens on health services.
more
Candid Conversations is a podcast where we talk to family planning and reproductive health champions from around the globe and take a deep dive into current topics in family planning and reproductive health, as well as the personal journeys of our champions, the challenges they’ve faced, what exci...tes them about the future and some advice for other up and coming leaders.
Our Goals:
Highlight the new generation of family planning leaders and the trailblazing work they are doing
Discuss the challenges youth face starting new programs and managing existing projects
Give a youth perspective on the needs of youth and the changing reproductive health landscape
Below are our latest episodes. Tune in by clicking below, listening to us on Apple podcasts, subscribing to our Youtube channel, or following us on Spotify.
more
Estas directrices sustituyen a los anteriores documentos de política de la OMS sobre el manejo de la ILTB en las personas con la infección por el VIH, los contactos del hogar de personas con TB y otros grupos de riesgo. Las Directrices unificadas de la OMS sobre la tuberculosis: Tratamiento preven...tivo de la tuberculosis se elaboraron conforme a los requisitos del Comité de Examen de Directrices. El grupo de elaboración de las directrices (GDG, por su sigla en inglés) examinó la calidad de la evidencia más reciente disponible sobre la efectividad y los posibles perjuicios, así como la certeza de la evidencia, los valores y las preferencias, además de cuestiones de equidad, utilización de recursos, aceptabilidad y viabilidad de la aplicación al actualizar o formular nuevas recomendaciones y determinar su fuerza.
more
Este manual operativo determina los aspectos y las etapas primordiales de la ampliación programática del tratamiento preventivo de la tuberculosis, y proporciona herramientas de ejecución e instrumentos de trabajo para la adaptación al contexto local, así como indicadores de seguimiento y evalu...ación de la gestión. En él se destacan los elementos clave que deben tenerse en cuenta en la atención al paciente, la planificación nacional estratégica y la movilización de recursos
more
Each year, rabies causes approximately 59,000 deaths worldwide. Despite evidence that control of dog rabies through animal vaccination programs and elimination of stray dogs can reduce the incidence of human rabies, dog rabies remains common in many countries and exposure to rabid dogs is still the ...cause of over 90% of human exposures to rabies and of 99% of human rabies deaths worldwide. CDC experts in the Poxvirus and Rabies Branch conduct an annual assessment of individual countries’ rabies status worldwide which considers the presence of wildlife rabies, canine rabies variant (dog rabies), and non-rabies lyssaviruses.
more
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and experti...se to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the ‘heath benefit’ return on investment in these programmes is truly a ‘best value in public health’. Many current donations are ‘open-ended’, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO’s new NTD roadmap to 2030.
more